NIH plans to test GLP-1s, other drugs for long COVID

Publication date: Sep 12, 2025

Later that day, patient advocate Mike Zissis, who lives with long COVID, had a chance to respond in remarks of his own. We need commitment. Similarly, Luke Liu, a physician at the clinic Neuroversion, described how stellate ganglion blocks had helped patients of his with long COVID (J. Neuroimmunol. 2021, DOI: 10. 1016/j. jneuroim. 2021. 577784) and Megan Carmilani, founder of the nonprofit Long Covid Families, described how low-dose naltrexone, or LDN, had helped her. There will be challenges with testing these interventions. Researchers came together last September for a kick-off meeting to discuss a path forward for such trials. We need candor. Most of them72%were from patients; another 11% came from universities, 7% from caregivers, 6% from companies, and 4% from research institutes. And it may be difficult to gain traction for LDN in clinical practice, especially among young children.

Semantics